Form 4: Guardant Health CTO's RSU Vesting & Tax Withholding

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent share disposition for tax obligations on October 1, 2025.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc., reported transactions on October 1, 2025.
• A total of 16,104 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• These acquisitions included 1,339 shares from an RSU award granted on November 7, 2022; 1,668 shares from an RSU award granted on December 13, 2023; and 13,097 shares from an RSU award granted on November 8, 2024.
• Concurrently, 8,163 shares of common stock were disposed of at a price of $62.65 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Darya Chudova beneficially owns 89,390 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine, scheduled executive compensation event (RSU vesting) and subsequent tax-related share disposition. While the vesting is positive for the executive, the overall impact on the company's financial health or strategic direction is neutral, as it is an expected part of compensation.

Positives

• The vesting of 16,104 restricted stock units indicates continued compensation and retention of a key executive.
• The transactions reflect the execution of pre-scheduled equity compensation plans, demonstrating stability in executive incentives.

Negatives

• 8,163 shares were disposed of to satisfy tax withholding obligations, resulting in a reduction of direct share ownership by the Chief Technology Officer.

Future Outlook

Remaining portions of the restricted stock unit awards are scheduled to vest in equal quarterly installments over the next two to three years, indicating continued equity compensation for the Chief Technology Officer.

Industry Context

This filing details a routine insider transaction related to executive compensation, which is a standard practice across all industries for publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• Shareholders: Minor, routine dilution from RSU vesting is expected as part of compensation plans. The disposition for taxes is a standard practice and does not reflect a change in company fundamentals.
• Employees: Reinforces the company's commitment to equity-based compensation for key executives.

Next Steps

• Remaining 75% of the November 7, 2022 RSU award vests in equal quarterly installments over the remaining three-year period after October 1, 2023.
• Remaining 67% of the December 13, 2023 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2024.
• Remaining 67% of the November 8, 2024 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2025.

Key Dates

Recommendation

This Form 4 details a routine, scheduled insider transaction involving the vesting of restricted stock units and subsequent share disposition for tax purposes. Such events are part of standard executive compensation and do not typically provide new material information that would warrant a change in investment recommendation. The filing does not offer insights into the company's operational performance, strategic direction, or financial health beyond this compensation event.

Keywords

Guardant Health, GH, Darya Chudova, Chief Technology Officer, CTO, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Equity Compensation, Tax Withholding